- Home
- SPKL vs LCTX Comparison
SPKL vs LCTX Comparison
Compare SPKL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPKL
- LCTX
- Stock Information
- Founded
- SPKL 2021
- LCTX 1990
- Country
- SPKL United States
- LCTX United States
- Employees
- SPKL N/A
- LCTX N/A
- Industry
- SPKL
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPKL
- LCTX Health Care
- Exchange
- SPKL Nasdaq
- LCTX Nasdaq
- Market Cap
- SPKL 174.6M
- LCTX 110.2M
- IPO Year
- SPKL 2023
- LCTX N/A
- Fundamental
- Price
- SPKL $10.66
- LCTX $0.55
- Analyst Decision
- SPKL
- LCTX Strong Buy
- Analyst Count
- SPKL 0
- LCTX 5
- Target Price
- SPKL N/A
- LCTX $4.80
- AVG Volume (30 Days)
- SPKL 44.7K
- LCTX 2.9M
- Earning Date
- SPKL 01-01-0001
- LCTX 03-06-2025
- Dividend Yield
- SPKL N/A
- LCTX N/A
- EPS Growth
- SPKL N/A
- LCTX N/A
- EPS
- SPKL 0.19
- LCTX N/A
- Revenue
- SPKL N/A
- LCTX $8,719,000.00
- Revenue This Year
- SPKL N/A
- LCTX N/A
- Revenue Next Year
- SPKL N/A
- LCTX $41.15
- P/E Ratio
- SPKL $57.45
- LCTX N/A
- Revenue Growth
- SPKL N/A
- LCTX N/A
- 52 Week Low
- SPKL $10.18
- LCTX $0.48
- 52 Week High
- SPKL $11.95
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- SPKL 61.06
- LCTX 47.26
- Support Level
- SPKL $10.63
- LCTX $0.51
- Resistance Level
- SPKL $10.66
- LCTX $0.60
- Average True Range (ATR)
- SPKL 0.02
- LCTX 0.04
- MACD
- SPKL 0.00
- LCTX 0.01
- Stochastic Oscillator
- SPKL 75.00
- LCTX 53.85
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.